Annexon Inc. has announced the appointment of Lloyd Clark, M.D., as senior vice president of ophthalmology strategy and innovation. Dr. Clark, a retina specialist with over 25 years of experience, will focus on advancing the company's ophthalmology program, particularly the Phase 3 ARCHER II trial for ANX007, aimed at treating dry age-related macular degeneration with geographic atrophy. The trial is expected to complete enrollment in the third quarter of 2025, with topline data anticipated in the second half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.